Intelligence for biotech portfolios, partnering, and company visibility

Value in one line: turn scattered public science into comparable decisions (where to play), coherent external surfaces (how you show up), and explicit financing shapes (what paths fit)—each with a named method and tangible artifact, not a generic consulting menu.

Biotica Bio helps science-based biotech teams evaluate opportunities, frame assets for investors and partners, and tighten discoverability—independently and with traceable evidence where scoped.

Three offers

Offer Best for Core artifact
Portfolio Intelligence System Funds, CEOs, BD teams Biotica Opportunity Map — structured map, scoring, executive synthesis
Visibility & Narrative System Startups / portfolio companies Biotica Discoverability Layer — implemented narrative and discoverability infrastructure
Strategic Capital Options System Later-stage or financing-stressed companies Biotica Capital Pathways Matrix — non-dilutive and structured financing paths

See how the offers fit together →

Evidence: Portfolio Intelligence uses Open Targets and Orange Book (and other public layers) as scoped inputs to opportunity maps and memos—not the umbrella brand. Evidence and tools →

Choose your path

Next step

Deliverables are scoped to your entities—we do not ship generic “example reports” as proof. For how each artifact differs using Open Targets + Orange Book on the same illustration, see the IaIP blood-product thread on What we do. Request a scoped proposal → or review How it’s built for reproducible evidence workflow.

Evidence and reproducibility

Where we pull Open Targets and other public layers, assessments stay traceable and re-runnable. How it’s built · The platform

Structure-informed diligence (Open Targets + Orange Book + optional AlphaFold-class reads) is an optional module under Portfolio Intelligence—learn more →


Powered by public evidence where scoped. Interpretation and product design by Biotica Bio.


About